Zoetis (ZTS) has opened 2026 with Q1 revenue of US$2.3b and basic EPS of US$1.42, setting the tone for how investors read the latest earnings update. The company has seen quarterly revenue move from US$2.2b in Q1 2025 to US$2.3b in Q1 2026, while basic EPS shifted from US$1.41 to US$1.42 over the same period, giving you a clear view of how the top and bottom lines are tracking year on year. Against that backdrop, the focus now is on how sustainably Zoetis is converting this revenue into profits and what that means for margins going forward.

See our full analysis for Zoetis.

With the numbers on the table, the next step is to set them against the widely held narratives around Zoetis to see which storylines hold up and which ones the latest results start to question.

Margins Hold Firm Around 28%

• Over the last 12 months, Zoetis generated US$9.5b in revenue and US$2.7b in net income, which works out to a 28% net margin compared with 27.1% a year earlier.
• Bullish investors often highlight that this high margin base sits alongside product and channel growth stories. However, the latest quarter shows net income of US$601 million on US$2.3b of revenue versus US$631 million on US$2.2b a year ago, which means:
  • Profitability is still strong in absolute terms, but the Q1 net income figure is slightly lower year on year even though revenue is higher, so the margin expansion that some bulls discuss is not clearly visible in this single quarter.
  • Trailing earnings grew 6.1% over the past year and five year earnings growth averaged 7.5% per year, which supports the idea of a resilient earnings engine but not the kind of rapid acceleration some bullish narratives point to.

Bulls argue that resilient margins and growing franchises can still support a long runway, so if you want to see how that argument is built from the ground up, 🐂 Zoetis Bull Case

P/E Of 13.7x Versus Peers At 22.4x

• The stock is shown trading on a trailing P/E of 13.7x, compared with a peer group at 22.4x and a US Pharmaceuticals average of 16.1x, and the DCF fair value in the data is US$211.27 versus the current share price of US$87.31.
• Critics point out in the bearish narrative that slower expected growth could justify a lower multiple, and the current numbers give them some support, because:
  • Analysts in the data expect revenue growth of about 4.8% per year and earnings growth of roughly 6.8% per year, both below the cited US market forecasts of 11.5% revenue growth and 16.6% earnings growth.
  • The same dataset flags a high level of debt as a minor risk and a 2.43% dividend yield, so part of the lower P/E may reflect investors weighing balance sheet risk and moderate growth against the income stream and DCF fair value estimate.

Skeptics focus on whether that lower P/E is a warning sign rather than an opening, and you can see their full case set out in the 🐻 Zoetis Bear Case

Analyst Target Of US$147.00 Versus US$87.31 Price

• The analysis data cites an analyst price target of US$147.00 compared with the current share price of US$87.31, while trailing earnings per share over the last 12 months sit at US$6.11.
• Consensus style narratives refer to meaningful long term potential backed by unmet demand and recurring revenue, and the figures here give both support and some pushback, because:
  • On one hand, the 28% net margin, US$2.7b of trailing net income and ongoing earnings growth of 6.1% over the past year show a business that is already very profitable at scale.
  • On the other hand, the same forecasts show revenue growth of 4.8% and earnings growth of about 6.8% per year, which are below the US market numbers in the dataset, so the gap between US$87.31 and the US$147.00 target assumes the market continues to value cash generation highly even if top line growth stays more modest.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Zoetis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers and narratives so far. If you want to move quickly and make your own call, start by weighing up 6 key rewards and 1 important warning sign.

See What Else Is Out There

Zoetis combines strong profitability with relatively modest forecast revenue and earnings growth versus the broader US market, which may limit potential upside for growth focused investors.

If that slower growth profile gives you pause, use the 51 high quality undervalued stocks to quickly spot companies where solid fundamentals and lower expectations could work more in your favor.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.